248 related articles for article (PubMed ID: 36689623)
1. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade.
Pearce H; Croft W; Nicol SM; Margielewska-Davies S; Powell R; Cornall R; Davis SJ; Marcon F; Pugh MR; Fennell É; Powell-Brett S; Mahon BS; Brown RM; Middleton G; Roberts K; Moss P
Cancer Immunol Res; 2023 Apr; 11(4):435-449. PubMed ID: 36689623
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and TIGIT coexpressing CD8 + CD103 + tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy.
Jiang F; Mao M; Jiang S; Jiao Y; Cao D; Xiang Y
Int Immunopharmacol; 2024 Jan; 127():111381. PubMed ID: 38150880
[TBL] [Abstract][Full Text] [Related]
3. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
[No Abstract] [Full Text] [Related]
4. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer.
Heiduk M; Klimova A; Reiche C; Digomann D; Beer C; Aust DE; Distler M; Weitz J; Seifert AM; Seifert L
Clin Cancer Res; 2023 Jul; 29(14):2638-2650. PubMed ID: 37140899
[TBL] [Abstract][Full Text] [Related]
5. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
[TBL] [Abstract][Full Text] [Related]
7. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
8. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
[No Abstract] [Full Text] [Related]
9. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
11. Fatty Acid Oxidation Controls CD8
Lin R; Zhang H; Yuan Y; He Q; Zhou J; Li S; Sun Y; Li DY; Qiu HB; Wang W; Zhuang Z; Chen B; Huang Y; Liu C; Wang Y; Cai S; Ke Z; He W
Cancer Immunol Res; 2020 Apr; 8(4):479-492. PubMed ID: 32075801
[TBL] [Abstract][Full Text] [Related]
12. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
13. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
14. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
15. LAG3 and TIGIT Expression on Tumor-Infiltrating Lymphocytes in Cutaneous Melanoma.
Naimy S; Bzorek M; Eriksen JO; Løvendorf MB; Litman T; Dyring-Andersen B; Gjerdrum LMR
Dermatology; 2024; 240(1):156-163. PubMed ID: 37952520
[TBL] [Abstract][Full Text] [Related]
16. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
17. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
18. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
19. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
20. TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Josefsson SE; Beiske K; Blaker YN; Førsund MS; Holte H; Østenstad B; Kimby E; Köksal H; Wälchli S; Bai B; Smeland EB; Levy R; Kolstad A; Huse K; Myklebust JH
Cancer Immunol Res; 2019 Mar; 7(3):355-362. PubMed ID: 30659053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
